Skip navigation.

Adipogenic and Metabolic Effects of Antipsychotic Drugs

Forms: Download Registration Form in either: Microsoft Word
Held On: Mon 7/11/2011 - Tue 7/12/2011
Location: Hilton Newark Airport
1170 Spring Street
Elizabeth, NJ 07201
Conference Welcome Package
Overview:

Though possessing many advantages, many Antipsychotic drugs (APDs) have a major liability in their ability to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population. The past decade has witnessed substantial research effort aimed at quantifying, understanding, preventing, and alleviating these adverse effects and our goal is to provide a scientific update of these findings and discuss future research needs.

Organizing
Committee:

David Allison, Ph.D.
University of Alabama at Birmingham

John Newcomer, M.D.
Miller School of Medicine, University of Miami

Christoph Correll, M.D.
Albert Einstein College of Medicine

Gary Remington MD PhD FRCPC
Centre for Addiction and Mental Health (CAMH), Canada

Elaine H. Morrato, DrPH MPH CPH
University of Colorado Denver

Schedule of Events:

DATE TIME SPEAKER/MODERATOR TOPIC VIDEO
Day 1 8:00 - 8:05 David B. Allison, Ph.D., University of Alabama at Birmingham Announcements/Business  
I. Magnitude and frequency of obesity, diabetes, and other metabolic disturbances among relevant patient populations.
8:05 - 8:10 David B. Allison, PhD Overview by Moderator  
8:10 - 8:40 John Newcomer, MD, Miller School of Medicine, University of Miami Introduction and Scope of the Problem video
8:40 - 9:10 Marianne Ulcickas Yood, DSc, MPH, EpiSource, New York Adoption of Metabolic Monitoring & Risk Management Practices video
9:10 - 9:40 Karen Teff, PhD, University of Pennsylvania Atypical Antipsychotics: effects on post-prandial metabolism in healthy subjects, independent of weight gain or psychiatric disease Video not available
9:40 - 10:05 All speakers led by Moderator Panel Discussion  
10:05 - 10:20 Break
II. The magnitude of the adverse metabolic effects, how they differ by drug, and drugs on the horizon with more benign metabolic profiles.
10:20 - 10:25 Julia M Gohlke, PhD, University of Alabama at Birmingham Overview by Moderator  
10:25 - 10:55 Ginger Nicol MD, Washington University Human studies of the effects of APDs on adiposity. video
10:55 - 11:25 David C. Henderson, MD, Harvard University Human studies of the effects of APDs on glucose metabolism and other metabolic syndrome features. video
11:25 - 11:55 Christopher J Lynch, PhD Penn State University Metabolomics and metabolic phenotyping after exposure to side effect prone atypical antipsychotics video
11:55 - 12:25 Christoph Correll, MD, Albert Einstein College of Medicine Effects in children, adolescents, and first-break patients video
12:25 - 12:50 All speakers led by Moderator Panel Discussion  
12:25 - 2:00 Lunch
III. The biochemical, molecular, and mechanisms of these adverse APD effects.
2:00 - 2:05 Dilip V. Jeste, MD, University of California, San Diego Overview by Moderator  
2:05 - 2:35 Donard S. Dwyer, PhD, Louisiana State University Findings in invertebrate models: Basic mechanisms, neurotransmitter regulation, and neuroprotection. video
2:35 - 3:05 Marilyn Ader, PhD, University of Southern California Findings in mammalian models: Physiologic effects on endocrine regulation and dysregulation. video
3:05 - 3:15 Break
3:15 - 3:45 Henry Nasrallah, MD, University of Cincinnati The links between metabolic disorders and cognitive impairments video
3:45 - 4:25 Anil K. Malhotra, MD, Albert Einstein College of Medicine Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. video
4:25 - 4:50 All speakers led by Moderator Panel Discussion  
DATE TIME SPEAKER/MODERATOR TOPIC VIDEO
Day 2 8:00 - 8:05 David B. Allison, Ph.D., University of Alabama at Birmingham Announcements/Business  
IV. The behavioral and energetic mechanisms of these adverse APD effects
8:05 - 8:10 Vicki L. Ellingrod Ringold, PharmD, University of Michigan Overview by Moderator  
8:10 - 8:45 Gary Remington MD PhD FRCPC, Centre for Addiction and Mental Health (CAMH), Canada Rodent Models: a Viable Option? video
8:45 - 9:20 Vicki L. Ellingrod Ringold, PharmD, University of Michigan Antipsychotics, N-3 fatty acids, and pharmacogenetic factors video
9:20 - 9:55 Kimberly A. Brownley, PhD, University of North Carolina, Chapel Hill Human intake studies. video
9:55 - 10:25 All speakers led by Moderator Panel Discussion  
10:25 - 10:35 Break
V. The safety and efficacy of treatment and prevention strategies to reduce these adverse effects
10:35 - 10:40 Mary T. Weber, PhD, APRN, BC, PMHNP, University of Colorado Denver Overview by Moderator  
10:40 - 11:10 Rohan Ganguli, MD, University of Pittsburgh at Pittsburgh Lifestyle treatments to reduce adverse weight and metabolic effects video
11:10 - 11:40 Trino Baptista, MD, PhD, Los Andes University Medical School, Mérida, Venezuela Pharmacologic treatments to reduce adverse weight & metabolic effects video
11:40 - 12:10 Tony Cohn, MB ChB FRCPC, Department of Psychiatry, University of Toronto What are the metabolic benefits in switching antipsychotics and what are the risks? video
12:10 -12:35 All speakers led by Moderator Panel Discussion  
12:35 - 1:45 Lunch
VI. Methodological issues
1:45 - 1:50 John Newcomer, M.D., Miller School of Medicine, University of Miami Overview by Moderator  
1:50 - 2:20 David B. Allison, PhD, University of Alabama at Birmingham Methodological issues in designing, analyzing, and interpreting randomized clinical trials of APD metabolic effects video
2:20 - 2:50 Elaine H. Morrato,DrPH, University of Colorado Denver Methodologic issues in epidemiologic and pharmacovigilance studies of APD metabolic effects. video
2:50 - 3:05 Break
VII. Translational Science & Personalized Medicine
3:05 - 3:10 Lydia Chwastiak, MD, PhD, Yale University Overview by Moderator  
3:10 - 3:40 Stephen Crystal, PhD, Rutgers University Broadened Use of Atypical Antipsychotics: Trends and Challenges for Policymakers, Clinicians, and Patients video
3:40 - 4:10 Deanna Kelly, PharmD, University of Maryland Metabolic and behavioral predictors of response and their implications for choice of treatment. video
4:10 - 4:35 All speakers led by Moderator Panel Discussion  


UAB Speakers:


External Speakers:


Contact Information:

Logistics: Jeff Allison
University of Alabama at Birmingham
1530 3rd Avenue South
Webb 402 3361
Birmingham, AL 35294-3361
Phone: (205) 975-9675
Email: norc@uab.edu
  Scientific: David B. Allison, Ph.D.
University of Alabama at Birmingham
1665 University Blvd, RPHB 420C
Birmingham, AL 35294-0022
Phone: (205) 975-9169
Email: dallison@uab.edu


Funded by:

Funding for this conference was made possible (in part) by (R13MH086166) from the National Institute of Mental Health (NIMH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S Government.
 

Sponsors:

Nutrition Obesity Research Center,
University of Alabama at Birmingham
 

Contributors:

Women, members of underrepresented minority groups and individuals with disabilities are strongly encouraged to apply.


**NOTE: You will need RealOne Player to view videos. To install RealOne Player, please Click here